[
  {
    "ts": "2025-12-03T13:30:00+00:00",
    "headline": "BlackRock Bolsters Outcome ETF Suite with Nasdaq Premium Income Strategy",
    "summary": "NEW YORK, December 03, 2025--Today, BlackRock expanded its outcome ETF suite with the launch of the iShares Nasdaq Premium Income Active ETF (Nasdaq:BALQ). BALQ aims to provide current income while capturing the growth potential of innovation leaders in the Nasdaq 100 Index.",
    "url": "https://finance.yahoo.com/news/blackrock-bolsters-outcome-etf-suite-133000390.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "ccf9adca-2542-32e6-8916-069251a48f78",
      "content": {
        "id": "ccf9adca-2542-32e6-8916-069251a48f78",
        "contentType": "STORY",
        "title": "BlackRock Bolsters Outcome ETF Suite with Nasdaq Premium Income Strategy",
        "description": "",
        "summary": "NEW YORK, December 03, 2025--Today, BlackRock expanded its outcome ETF suite with the launch of the iShares Nasdaq Premium Income Active ETF (Nasdaq:BALQ). BALQ aims to provide current income while capturing the growth potential of innovation leaders in the Nasdaq 100 Index.",
        "pubDate": "2025-12-03T13:30:00Z",
        "displayTime": "2025-12-03T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/99c42edf9aedaaa73114983f37e74331",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SyVjAsFCLSOEtwyFwOmOaA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/99c42edf9aedaaa73114983f37e74331.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tGpqwkxtVxWdC4_geveREw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/99c42edf9aedaaa73114983f37e74331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/blackrock-bolsters-outcome-etf-suite-133000390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/blackrock-bolsters-outcome-etf-suite-133000390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BLK"
            },
            {
              "symbol": "^NDX"
            },
            {
              "symbol": "CBOE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T13:30:00+00:00",
    "headline": "Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood",
    "summary": "BIOMIND LABS ACCELERATES FDA PATHWAY FOR 5-MEO-DMT CANDIDATE BMND08 AND GRANTS STOCK OPTIONS TORONTO, ON / ACCESS Newswire / December 3, 2025 /Biomind Labs Inc. (\"Biomind\" or the \"Company\") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI), a clinical-stage ...",
    "url": "https://finance.yahoo.com/news/biomind-labs-accelerates-fda-pathway-133000057.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "dea8e4c2-0fca-3bcf-b011-19ef259681c8",
      "content": {
        "id": "dea8e4c2-0fca-3bcf-b011-19ef259681c8",
        "contentType": "STORY",
        "title": "Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood",
        "description": "",
        "summary": "BIOMIND LABS ACCELERATES FDA PATHWAY FOR 5-MEO-DMT CANDIDATE BMND08 AND GRANTS STOCK OPTIONS TORONTO, ON / ACCESS Newswire / December 3, 2025 /Biomind Labs Inc. (\"Biomind\" or the \"Company\") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI), a clinical-stage ...",
        "pubDate": "2025-12-03T13:30:00Z",
        "displayTime": "2025-12-03T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biomind-labs-accelerates-fda-pathway-133000057.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biomind-labs-accelerates-fda-pathway-133000057.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMNDF"
            },
            {
              "symbol": "CBOE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]